Rhox homeobox family member 1 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored RHOXF1P1 profile across patient tissues and cancer cell-line models. RHOXF1P1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, RHOXF1P1 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, RHOXF1P1 RNA expression shows 11,439 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ESCA, KIRC, and ACC as cancer lineages where RHOXF1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHOXF1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHOXF1P1 survival associations across molecular data types. RHOXF1P1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHOXF1P1 RNA expression–survival associations across cancer types. High RHOXF1P1 expression shows unfavorable associations in ESCA, THCA, UVM, LIHC, STAD and LUAD. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ESCA as the clearest survival context for RHOXF1P1 RNA expression.
This table summarizes RHOXF1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RHOXF1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHOXF1P1 shows lower tumor expression in LUAD, THCA and LUSC and higher tumor expression in KIRC, HNSC and BRCA. The KIRC box plot shows higher RHOXF1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.489, t-test p < 0.001).
This table shows molecular features associated with RHOXF1P1 in patient tissues and cancer cell lines. In patient samples, RHOXF1P1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
